Tenet Healthcare Corporation (THC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a positive outlook with raised guidance for EBITDA and revenues, strong free cash flow, and a solid leverage ratio. Share repurchases and strategic capital allocation further enhance shareholder value. Despite some deceleration in USPI growth, management's confidence in handling demand and inflationary pressures suggests stability. The Q&A insights reinforce the company's growth strategies and operational efficiencies, supporting a positive sentiment.
Key Financial Performance
Net Operating Revenues $5.3 billion in Q3 2025, with no specific year-over-year percentage change mentioned.
Consolidated Adjusted EBITDA $1.1 billion in Q3 2025, a 12% increase year-over-year, driven by strong same-store growth and operating efficiency.
Adjusted EBITDA Margin 20.8% in Q3 2025, a 170 basis points improvement year-over-year, attributed to same-store growth and operating efficiency.
USPI Adjusted EBITDA $492 million in Q3 2025, a 12% increase year-over-year, supported by 8.3% same-facility revenue growth and 11% growth in total joint replacements in ASCs.
Hospital Segment Adjusted EBITDA $607 million in Q3 2025, a 13% increase year-over-year, with same-store hospital admissions up 1.4% and revenue per adjusted admission up 5.9%.
Free Cash Flow $778 million in Q3 2025, amounting to $2.16 billion year-to-date, a 22% increase over the same 9-month period in the prior year, driven by strong cash collection performance.
Leverage Ratio 2.3x EBITDA as of September 30, 2025, reflecting operational performance and financial discipline.
Share Repurchases 598,000 shares repurchased for $93 million in Q3 2025, totaling 7.8 million shares for $1.2 billion year-to-date.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New hospital facility in Port St. Lucie, Florida: Opened in September 2025, expanding capacity in a fast-growing area. The hospital offers comprehensive emergency and specialty care, leveraging state-of-the-art technology, including robotics and advanced cardiac catheterization techniques.
M&A and de novo activity: Acquired 11 centers and opened 2 de novo centers in Q3 2025, focusing on high-acuity procedures like spine and orthopedics. Nearly $300 million spent on M&A year-to-date, with plans for further additions in Q4.
Revenue and EBITDA growth: Q3 2025 net operating revenues reached $5.3 billion, with consolidated adjusted EBITDA growing 12% year-over-year to $1.1 billion. Adjusted EBITDA margin improved to 20.8%, driven by same-store growth and operational efficiency.
USPI performance: Generated $492 million in adjusted EBITDA, a 12% year-over-year growth. Same-facility revenues grew by 8.3%, with an 11% increase in total joint replacements in ASCs.
Hospital segment performance: Adjusted EBITDA grew 13% to $607 million in Q3 2025. Same-store hospital admissions increased by 1.4%, and revenue per adjusted admission rose by 5.9%.
Increased investment in capital expenditures: 2025 capital expenditure guidance raised to $875 million-$975 million, a $150 million increase at the midpoint, to support organic growth.
Free cash flow guidance: 2025 free cash flow minus NCI guidance increased to $1.495 billion-$1.695 billion, reflecting EBITDA growth and strong cash collection performance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Enhanced premium tax subsidies uncertainty: Uncertainty about the enhanced premium tax subsidies and their impact on reimbursement and enrollment in the exchanges for 2026 could pose financial and operational risks.
State-directed payment program approvals: Pending approvals for increases in state-directed payment programs for 2026 create uncertainty in financial planning and revenue projections.
Medicaid supplemental revenues: The reliance on Medicaid supplemental revenues related to prior years introduces variability and potential unpredictability in financial results.
Labor costs and contract labor expenses: Although labor costs have improved, managing salary, wages, and benefits, as well as contract labor expenses, remains a challenge in maintaining operational efficiency.
Debt maturities and financial flexibility: While no significant debt maturities are due until 2027, maintaining a deleveraged balance sheet and financial flexibility is critical to support capital allocation priorities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2025 Adjusted EBITDA Guidance: Raised to a range of $4.47 billion to $4.57 billion, reflecting an 11% increase at the midpoint from initial guidance.
Capital Expenditures for 2025: Increased to $875 million to $975 million, a $150 million increase at the midpoint over prior expectations, to support organic growth.
Free Cash Flow Minus NCI for 2025: Raised to a range of $1.495 billion to $1.695 billion, an increase of $250 million at the midpoint from previous guidance.
2026 Hospital Segment Outlook: Healthy patient demand expected to support same-store volume growth and a stable operating environment, supported by disciplined cost controls.
2026 USPI Outlook: Same-store revenue growth expected in line with long-term expectations, with a focus on high-acuity cases, operational efficiencies, and disciplined cost controls. Further contributions anticipated from M&A and de novo development.
2025 Consolidated Net Operating Revenues: Expected in the range of $21.15 billion to $21.35 billion, an increase of $150 million over prior expectations.
2025 Free Cash Flow: Expected in the range of $2.275 billion to $2.525 billion, reflecting strong cash collection performance and EBITDA growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: During the third quarter, the company repurchased 598,000 shares of stock for $93 million. Year-to-date through September 30, the company has repurchased 7.8 million shares for $1.2 billion.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the expectations for Q4 utilization and capacity at USPI, and how does exchange exposure impact USPI?
A:Management has not built in expectations for higher utilization due to exchange subsidies expiring and does not anticipate a rush in demand. They are confident in USPI's capacity to handle typical end-of-year demand, with staffing and capacity planning done months in advance. USPI has less exposure to exchange business compared to the hospital segment, as exchange members behave more like Medicaid patients. In Q3, exchange admissions were 8.4% of total admissions and 7% of total consolidated revenues.
Q:What is the reason for the increase in CapEx guidance, and how is the capital being allocated?
A:The increase in CapEx guidance is due to investments in clinical program infrastructure, service line support, and growth strategies in hospitals. This includes high-acuity areas like cardiac care, intensive care, cath labs, imaging, and surgical programs. The demand environment remains healthy, and management sees opportunities for growth.
Q:What is driving the increase in free cash flow guidance, and are these trends sustainable?
A:The increase in free cash flow guidance is driven by improved cash collections at Conifer, EBITDA growth, and better working capital management. Deleveraging has also reduced interest expenses. Management believes these operational efficiencies are sustainable over the long term.
Q:Why does the implied Q4 guidance for USPI show a deceleration in year-over-year growth?
A:The deceleration is due to larger scale assets and pricing elements lapping year-over-year. Management views this as a mathematical effect rather than a change in business demand or organic performance.
Q:What are the expectations for labor and inflationary pressures in 2026?
A:Management expects the labor environment to remain strong, with no significant changes anticipated. They are confident in managing inflationary pressures, including tariffs, through sourcing optimization and contracting efforts.
Q:How did Conifer perform in Q3, and can it assist with patient eligibility and enrollment if ACA exchange subsidies expire?
A:Conifer performed well in Q3, meeting expectations. It has capabilities to assist with patient eligibility and enrollment, including during Medicaid redeterminations. Management is also preparing for potential dislocations in exchange enrollment timelines.
Q:What service lines or geographies drove ASC and acute care volumes in Q3?
A:ASC volumes were driven by higher-acuity services like ortho, spine, robotics, and a healthier GI recovery. Acute care volumes were strong in trauma and high-acuity emergency visits, while respiratory and infectious disease volumes were lower than expected.
Q:What was the contribution from DPP and provider taxes in Q3, and what is the updated estimate for the year?
A:In Q3, supplemental Medicaid programs contributed $346 million, including $38 million from prior years. Year-to-date contributions are $1.02 billion, with $148 million being out-of-period payments. Management expects this to normalize in 2026.
Q:How is capital being allocated between USPI acquisitions and share buybacks?
A:USPI acquisitions have exceeded initial guidance due to a broader pipeline and competitive wins. Management remains focused on executing M&A and de novo strategies. Share buybacks have been active but lower in Q3 due to market uncertainty.
Q:Are there opportunities for expense management or AI deployment in 2026?
A:Management is exploring opportunities in labor costs, automation, and leveraging the Global Business Center. They are also investing in Conifer to improve collections. AI deployment was not specifically mentioned.
Q:What is the impact of the removal of the inpatient-only list on the enterprise?
A:The removal of the inpatient-only list could benefit USPI by pushing more cases into the outpatient setting. The impact on the acute care hospital segment would be less significant due to its focus on high-acuity work.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the sustainability of trends into 2026, particularly regarding inflationary pressures and the potential impact of the inpatient-only list removal. They also did not quantify the impact of the Wiser program or provide a detailed breakdown of CapEx allocation beyond general categories.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASCs de
ASCs rate
Approvals increase
Commission Saum
Florida facility
Lucie Florida
Mr Vice
Port St
Saum expectation
St Lucie
Tenet
Uncertainty tax
activity center
acuity hospital
addition investment
area country
art technology
asset bed
bed level
benefit USPI
business future
capacity area
capital portfolio
care state
case efficiency
catheterization technique
center de
collection point
confidence midpoint
contribution de
control acuity
country hospital
date center
de novo
demand store
development USPI
efficiency USPI
increase midpoint
THC Transcript
Tenet Healthcare Corporation (THC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Tenet Healthcare Corporation (THC) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call summary shows mixed results. Basic financial performance is stable, but no year-over-year growth in key metrics. Product development is positive with high-acuity service growth. Market strategy is stable, with successful M&A but no groundbreaking changes. Expenses are managed well, but concerns about payer denials and Medicaid trends persist. Shareholder returns are positive with share repurchases. Q&A insights reveal stable but unimproved payer dynamics and some strategic successes, balancing out the lack of strong guidance changes. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Tenet Healthcare Corporation (THC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Tenet Healthcare Corporation (THC) Q4 2025 Earnings Call Transcript
Positive2-11
The earnings call summary indicates positive sentiment with raised guidance for EBITDA and free cash flow, indicating strong financial performance. The Q&A section revealed management's focus on sustainable expense management and technology adoption, which are positive for long-term growth. While there are concerns about hospital admission growth and Medicaid payments, the overall tone remains optimistic. The company's emphasis on share buybacks and strategic investments further supports a positive outlook. Despite some uncertainties, the raised guidance and strategic initiatives suggest a positive stock price movement in the near term.
THC Slides
THC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
